These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Williams JV; Marks JG; Billingsley EM Br J Dermatol; 2000 Mar; 142(3):506-8. PubMed ID: 10735959 [TBL] [Abstract][Full Text] [Related]
7. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent. Esmaili N; Chams-Davatchi C; Valikhani M; Farshidfar F; Parvaneh N; Tamizifar B Eur J Dermatol; 2008; 18(2):159-64. PubMed ID: 18424375 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment with mycophenolate mofetil of four Japanese patients with pemphigus vulgaris. Koga H; Ishii N; Hamada T; Karashima T; Nakama T; Yasumoto S; Hashimoto T Eur J Dermatol; 2010; 20(4):472-5. PubMed ID: 20406724 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus. Doukaki S; Pistone G; Aricò M; Bongiorno MR Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):237-44. PubMed ID: 21192770 [TBL] [Abstract][Full Text] [Related]
10. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Mimouni D; Anhalt GJ; Cummins DL; Kouba DJ; Thorne JE; Nousari HC Arch Dermatol; 2003 Jun; 139(6):739-42. PubMed ID: 12810504 [TBL] [Abstract][Full Text] [Related]
11. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. Megahed M; Schmiedeberg S; Becker J; Ruzicka T J Am Acad Dermatol; 2001 Aug; 45(2):256-9. PubMed ID: 11464188 [TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris. Vyas N; Patel NS; Cohen GF J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris. Baskan EB; Yilmaz M; Tunali S; Saricaoglu H J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1432-4. PubMed ID: 19470052 [TBL] [Abstract][Full Text] [Related]
14. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Schütz E; Shipkova M; Armstrong VW; Wieland E; Oellerich M Clin Chem; 1999 Mar; 45(3):419-22. PubMed ID: 10053049 [No Abstract] [Full Text] [Related]
15. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil. Biot Sdel R; Franco JP; Lima RB; Pereira HN; Marques LP; Martins CJ An Bras Dermatol; 2014; 89(6):980-4. PubMed ID: 25387507 [TBL] [Abstract][Full Text] [Related]
16. Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study. De Simone C; Caldarola G; Perino F; Venier A; Guerriero G Dermatol Ther; 2012; 25(2):219-22. PubMed ID: 22741942 [TBL] [Abstract][Full Text] [Related]
17. A rare cause of unilateral facial rash. Krase IZ; Wickenheiser M; Chao J; Kurtzman D; Segal R; Culpepper K; Shi V Clin Exp Dermatol; 2019 Jun; 44(4):425-427. PubMed ID: 30229995 [No Abstract] [Full Text] [Related]
19. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. Ioannides D; Apalla Z; Lazaridou E; Rigopoulos D J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):855-60. PubMed ID: 21752101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]